The Crackdown on Compounded GLP-1 Meds Has Begun

Eli Lilly and Novo Nordisk are leading efforts to curb the sale of compounded GLP-1 medications. Lilly has issued hundreds of cease-and-desist letters to entities selling compounded tirzepatide, following the end of its FDA-declared shortage. Novo Nordisk, whose semaglutide drugs remain in shortage, is taking a different approach. The company published a peer-reviewed study in Pharmaceutical Research, highlighting quality concerns in compounded semaglutide samples, including lower-than-claimed strength and banned ingredients. These actions signal a broader industry pushback against compounders who entered the market during drug shortages. Wired adds: With mounting evidence that GLP-1s like tirzepatide are an effective treatment for other ailments beyond obesity and diabetes -- including addiction and Parkinson's disease -- demand is only expected to increase. It remains to be seen whether the pharmaceutical companies will be able to keep pace with the demand or if the meds will go back into shortage and compounders will be able to bound back into the market.

Read more of this story at Slashdot.